gefitinib has been researched along with pci 32765 in 8 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (pci 32765) | Trials (pci 32765) | Recent Studies (post-2010) (pci 32765) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,926 | 243 | 1,895 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Baumann, M; Becker, C; Engel, J; Goebel, L; Günther, G; Hengstler, JG; Hennes, E; Keul, M; Lategahn, J; Müller, H; Rauh, D; Schultz-Fademrecht, C; Smith, S; Tumbrink, HL; Unger, A | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Chen, L; Li, Y; Liu, K; Ma, T; Ma, X; Sun, H; Sun, X; Wang, C; Zheng, X; Zhu, Y | 1 |
| Ding, K; Lu, X; Smaill, JB | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
| Danilov, AV; Hamilton, BJ; Jones, JD; Rigby, WFC; Skopelja-Gardner, S | 1 |
2 review(s) available for gefitinib and pci 32765
| Article | Year |
|---|---|
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Topics: Chemistry, Pharmaceutical; Humans; Point Mutation; Protein Kinase Inhibitors | 2020 |
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |
6 other study(ies) available for gefitinib and pci 32765
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Male; Mice; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2017 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Idiopathic Pulmonary Fibrosis; Janus Kinase 3; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2020 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Cell Adhesion; Cell Adhesion Molecules; Gefitinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Monocytes; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Receptors, IgG; Rituximab; Signal Transduction; ZAP-70 Protein-Tyrosine Kinase | 2017 |